© 2014 The Texas Lawbook.
By Natalie Posgate – (October 27) – French animal health company Virbac has agreed to acquire major U.S. veterinary products from the global pharmaceutical company, Eli Lilly and Company. The assets are currently marketed by Novartis Animal Health.
The amount was not disclosed, but Virbac said in a company release that the assets it will acquire, two major parasiticides for dogs, are expected to reach approximately $90 to $100 million in 2014.
Dallas lawyers from Gibson, Dunn & Crutcher represented Virbac in the deal, with corporate partner Jeffrey Chapman as the lead attorney. Other attorneys on the M&A team included partner Jay Tabor and associates Caitlin Calloway and Joseph Orien.
Other Dallas Gibson Dunn attorneys on the deal included partners Tracey Davies (IP & technology licensing) and David Sinak (tax) and associate Krista Hanvey (employee benefits). Attorneys from the firm’s Orange County, New York, Century City and Washington, D.C. offices also advised.
In-house Virbac attorneys who played significant roles in the deal were General Counsel Florence Bambuck and Director of Legal, North America, Brett Haring. Virbac’s U.S. and Canada operations are headquartered in Fort Worth.
New York partner Raymond Geitz of Weil, Gotshal & Manges advised Eli Lilly.
The completion of the transaction is subject to approval by the Federal Trade Commission, as well as the closing of Eli Lilly’s acquisition of Novartis Animal Health.
© 2014 The Texas Lawbook. Content of The Texas Lawbook is controlled and protected by specific licensing agreements with our subscribers and under federal copyright laws. Any distribution of this content without the consent of The Texas Lawbook is prohibited.
If you see any inaccuracy in any article in The Texas Lawbook, please contact us. Our goal is content that is 100% true and accurate. Thank you.